{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-022600","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.448746+00:00","generated_at":"2026-06-04T20:01:08.764206+00:00","sec_items":["1.01","3.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Unicycive exchanges 43.6M Series A-2 preferred shares for 21,388 new preferred, amends warrants","bullets":["Exchanged 43,649,000 Series A-2 Preferred shares for 21,388.01 shares of new Series A-2 Prime Preferred.","Amended Tranche A, B, C warrants; reduced shares issuable, set exercise price at $1,000 per share.","New preferred series have conversion prices from $0.49 to $0.74 per share of common stock.","All prior Series A-1 through A-5 preferred eliminated via Certificates of Elimination.","Exchange treated as tax-free recapitalization under Sections 368(a)(1)(e) and/or 1036 of the Code."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-022600","json":"https://secwatch.observer/filing/0001213900-24-022600.json","markdown":"https://secwatch.observer/filing/0001213900-24-022600.md","text":"https://secwatch.observer/filing/0001213900-24-022600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024022600/0001213900-24-022600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024022600/ea0201786-8k_unicyc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:01:08.764206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb80b814b43814dbcf33bcfd93dc42947de3ebb4","claim":"Unicycive Therapeutics, Inc.: Filed Certificates of Elimination for five series of preferred stock and an Amended Certificate of Designation for new Series A Preferred Stock (effective 2024-03-14).","evidence_excerpt":"On March 13, 2024, the Company filed with the Delaware Secretary of State a Certificate of Elimination for each of the Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock and Series A-5 Convertible Preferred Stock. Each Certificate of Elimination was filed with an effective date of 12:01 a.m. ET on March 14, 2024.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024022600/0001213900-24-022600-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-14"}],"fact_type":"governance_change"},{"claim_id":"0158ab753ed5dec9af3afd1f1db9b33c4e42005f","claim":"Unicycive Therapeutics, Inc. entered into Exchange Agreement with certain accredited investors (effective 2024-03-13).","evidence_excerpt":"On March 13, 2024, Unicycive Therapeutics , Inc. (the “ Company ”) entered into an exchange agreement (the “ Exchange Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Investors surrendered an aggregate of 43,649,000 shares of Series A-2 Preferred Stock held by them in exchange for an aggregate of 21,388.01 shares of new preferred stock to be known as “Series A-2 Prime Preferred”","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024022600/0001213900-24-022600-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Effective","value":"2024-03-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}